Cargando…
Development of a point-of-care genetic test for effective treatment of ischaemic stroke: an early model-based cost-effectiveness analysis
Background: People who have experienced a stroke are at high risk of recurrent strokes. Clopidogrel is prescribed to people who have had a non-cardioembolic stroke. There is evidence that clopidogrel is not effective for patients with CYP2C19 loss-of-function alleles. Pharmacogenetic testing is a po...
Autores principales: | Wright, Stuart, McDermott, John, Sen, Dwaipayan, Smith, Craig, Newman, William, Payne, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587658/ https://www.ncbi.nlm.nih.gov/pubmed/37869733 http://dx.doi.org/10.12688/wellcomeopenres.19202.1 |
Ejemplares similares
-
The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack
por: McDermott, John H, et al.
Publicado: (2022) -
The rise of point-of-care genetics: how the SARS-CoV-2 pandemic will accelerate adoption of genetic testing in the acute setting
por: McDermott, John H., et al.
Publicado: (2021) -
Unravelling the Genetics of Ischaemic Stroke
por: Markus, Hugh S.
Publicado: (2010) -
Systemic innate myeloid responses to acute ischaemic and haemorrhagic stroke
por: Stephens, Ruth, et al.
Publicado: (2022) -
Genetics of ischaemic stroke in young adults
por: Terni, Eva, et al.
Publicado: (2014)